Anxa2 is a potential biomarker for cancer prognosis and immune in fi ltration: a systematic pan-cancer analysis

HIGHLIGHTS

SUMMARY

    After cardiovascular diseases, cancer is the second leading cause of death worldwide (Myerson et_al, 2019; Sung et_al, 2021; Siegel et_al, 2022). The RNA sequencing data was transformed into transcripts per million (TPM) reads and normalized by log2 transformation for the following analysis. treatments such as immunotherapy (Singh and McGuirk, 2020), cancer remains difficult to cure (Sung et_al, 2021; Siegel et_al, 2022). ANXA2 is involved in various pathophysiological processes, including epithelialmesenchymal transition, fibrinolysis and cancer drug resistance (Wang et_al, 2019; Huang et_al, 2022). ANXA2 is considered an autoantigen of autoimmune disorders like lupus nephritis, antiphospholipid . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?